Actuate to present elraglusib phase 2 topline data at the 2025 american society of clinical oncology (asco) annual meeting

- oral presentation at asco to highlight topline phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (gnp) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mpdac)
ACTU Ratings Summary
ACTU Quant Ranking